Our Strategy

Clearside Biomedical is a late-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary SCS™ microinjector to reach diseased tissue through the suprachoroidal space.

The key elements of our strategy are:

  • Advancing CLS-1001 and CLS-1003 to FDA approval under the Section 505(b)(2) regulatory pathway.
  • Maximizing the commercial potential of our product candidates.
  • Advancing our CLS-1002 wet AMD development program.
  • Developing a product candidate to treat diabetic macular edema (DME).
  • Developing additional therapies through collaborations with third parties.
  • Maintaining and strengthening our intellectual property portfolio.